Brain stem cell transplant aims to restore movement after stroke

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

KEY INCLUSION CRITERIA: 1. Confirmed diagnosis of completed ischemic subcortical stroke in the middle cerebral artery (MCA) distribution with or without cortical involvement based on magnetic resonance imaging (MRI) and/or computed tomography (CT) scan(s). 2. Index stroke occurred ≥ 6 months and ≤ 84 months prior to providing informed consent. 3. Age ≥ 18 years and ≤ 75 years at the time of providing informed consent. 4. Chronic motor neurological deficit due to the index stroke. 5. Total Fugl-Meyer Motor Scale (FMMS) \> 25 and ≤ 75 at baseline. 6. Modified Rankin Score (mRS) of 2-4 at baseline. 7. Subjects taking oral anti-spasticity agent (such as tizanidine hydrochloride or baclofen) must be on a stable dose for 90 days prior to a Screening/Baseline visit. KEY EXCLUSION CRITERIA: 1. Stroke lesion \<1 cm3 or \>100 cm3 as measured by MRI. 2. Previous history of symptomatic stroke(s) with incomplete motor recovery (NOT including index stroke). 3. Complete or near complete lack of right and/or left upper extremity and/or right and/or left lower extremity movement as defined by the MRC Scale for Muscle Strength scores. 4. History of any neuromuscular, rheumatologic, autoimmune, orthopedic, or other disease or condition that limits motor function. 5. Acute myocardial infarction (heart attack), acute pulmonary embolism (blood clot to the lungs), acute proximal deep vein thrombosis (blood clot in the leg or arm), acute peripheral arterial occlusion, or any other type of acute blood clotting episode within six (6) months of study screening. 6. Intracoronary and/or other intra-arterial stent placement within 12 months of study Screening/Baseline visits requiring uninterrupted anticoagulant and/or anti-platelet therapy. 7. Contracture involving a shoulder, elbow, wrist, finger, hip, knee, and/or ankle. 8. Any contraindication to stereotactic brain surgery. 9. Presence of serum anti-Human Leukocyte Antigen (HLA) Class I and/or Class II antibodies to donor NR1 cells with a Luminex assay value greater than the larger of the central lab's reference ULN or 3,000 Maximum Fluorescence Intensity.